Macfarlane Group's H1 2025: 13% revenue growth but profits halve as Packaging Distribution struggles. Manufacturing shines with acquisitions. Full-year guidance maintained.
This article covers information on Macfarlane Group PLC.
LON:MACFMacfarlane Group has posted a mixed set of interim results. Group revenue rose 13% to £146.6m, helped by the recently acquired Pitreavie and last year’s Polyformes deal. But profits fell sharply as Packaging Distribution faced weak demand, slower new business conversions and pressure on margins.
Management still expects the full year to be in line with market expectations, leaning on a seasonal H2 uplift, tighter cost control and acquisition synergies. The interim dividend is held at 0.96p and the share buyback continues.
| Metric | H1 2025 | H1 2024 | Change |
|---|---|---|---|
| Revenue | £146.6m | £129.6m | +13% |
| Adjusted operating profit (APM) | £9.8m | £12.5m | -22% |
| Operating profit (statutory) | £7.0m | £10.6m | -34% |
| Adjusted profit before tax | £7.9m | £11.6m | -32% |
| Profit before tax (statutory) | £5.0m | £9.7m | -49% |
| Adjusted diluted EPS | 3.78p | 5.37p | -30% |
| Diluted EPS (statutory) | 2.32p | 4.51p | -49% |
| Net cash from operating activities | £12.4m | £14.1m | -£1.7m |
| Net bank debt (30 June) | £15.2m | £9.0m | Higher |
| Pension scheme surplus (30 June) | £9.2m | £10.2m | Slightly lower |
| Interim dividend | 0.96p | 0.96p | Unchanged |
APMs remove non-cash items like the amortisation of acquired customer relationships and brand values, plus remeasurements of deferred contingent consideration. They’re useful for gauging underlying trading, but they are not a substitute for the statutory numbers.
Distribution – the bigger division at 75% of Group revenue – had a tough half. Revenue was broadly flat at £110.4m (H1 2024: £110.9m) as weak customer demand and slower decision-making dragged. New business wins were £3.7m versus £4.5m last year.
My take: this is the crux of the profit shortfall. The model relies on passing through input costs promptly and keeping the cost-to-serve lean. Neither held up in H1. The good news is Macfarlane has clear levers to pull in H2: price/mix discipline, cost efficiencies in sales, logistics and admin, and benefits from the new East Midlands distribution centre.
Manufacturing Operations did much of the heavy lifting. Revenue jumped to £39.2m (H1 2024: £21.3m), with £17.8m coming from Polyformes (acquired July 2024) and Pitreavie (January 2025). There was a sliver of organic growth too at 0.3%, including more supply into Distribution.
Related
Polar Capital Technology Trust sees 102% NAV growth in FY2026, beating its benchmark by 47 points thanks to AI and semiconductor exposure.
JoshuaJuly 10, 2026
Last updated
Category
InvestingViews
49 viewsLikes
No ratings yet
Why it matters: the strategy to balance the Group with a larger manufacturing footprint is working. It adds capability and cross-selling potential, and it is less exposed to the pure distribution margin squeeze. The next step is to pull through sales and cost synergies with Distribution and within Pitreavie.
| Revenue H1 2025 | Adj. operating profit H1 2025 | Adj. margin H1 2025 | Adj. margin H1 2024 | |
|---|---|---|---|---|
| Packaging Distribution | £110.4m | £4.8m | 4.3% | 8.4% |
| Manufacturing Operations | £39.2m | £5.0m | 12.7% | 15.1% |
Macfarlane continues to generate decent cash, with £12.4m net cash inflow from operating activities (H1 2024: £14.1m). Net bank debt increased to £15.2m at 30 June 2025, reflecting £16.5m spent on acquisitions and capex. The Group has a £40.0m bank facility running to 30 November 2027, with options to extend to November 2029, and is operating well within it.
The pension scheme remains a surplus at £9.2m (31 December 2024: £9.6m), and no further contributions are required. Finance costs rose to £2.1m (H1 2024: £0.9m), partly a function of higher borrowings and lease costs, which puts a premium on restoring margins in H2.
The interim dividend is maintained at 0.96p per share, payable on 9 October 2025 to shareholders on the register on 12 September 2025 (ex-dividend 11 September 2025). The Board also confirmed the recently launched share buyback programme will continue, although the size and pace are not disclosed.
Management guides to a better H2, citing seasonal trading, actions to manage input costs, and synergy delivery from Pitreavie. Full-year 2025 is expected to be in line with market expectations.
This is a classic mid-year reset. Revenue growth looks healthy, but profit fell as Distribution misfired on margins and costs. Manufacturing, boosted by Polyformes and Pitreavie, steadied the ship and gives Macfarlane more levers in higher value niches like aerospace and medical.
On balance, I see H2 as an execution test. If the team can push through price, land the new-business pipeline, wring costs out of the network and deliver Pitreavie synergies, the “full year in line” guidance looks achievable. The maintained dividend, ongoing buyback, pension surplus and ample bank facility provide reassurance while they get on with it. The flip side is clear too: if Distribution margins do not improve quickly, elevated finance costs will keep profits subdued.
For now, it is a hold-your-nerve story with catalysts in the second half. Keep an eye on Distribution gross margins, new business run-rate, and synergy delivery – they will likely determine how this year finishes.
Impax Q3 AUM rises to £23.3bn despite £1.7bn net outflows, driven by market gains and strong investment performance.
JoshuaJuly 10, 2026
MJ Gleeson FY2026 trading update: steady profits, mixed home sales with operational restructuring improving outlook.
JoshuaJuly 10, 2026
No comments yet - start the conversation.